1. In Vivo
  2. >>Innovation

Pixium Vision Won't Lose Sight Of Patient Needs In Drive For AMD Solution

 
• By Ashley Yeo

Keeping the patient at the center is just as important in the development of high-risk innovations that serve unmet needs as it is for all other medtech solutions. That is the view of Pixium Vision CEO Khalid Ishaque, whose company is on the cusp of taking many dry-AMD sufferers out of blindness with artificial bionic vision technology. It recently performed the first successful human implantation and activation of its Prima implant.

PRIMA cells
PRIMA Cells • Source: Pixium Vision

For innovators like Pixium Vision, which is developing a second-generation bionic vision restoration system, there are many bases to cover as the technology is shepherded through development, into trials, and some years later, into reimbursed use.

Positive news flow is a vital component for future funding, confidence building and convincing clinicians, so the French Euronext-listed company would have quietly rejoiced at the US FDA's January 2018 decision to permit a clinical feasibility study of Prima, its miniaturized wireless

Shortly prior to that, Pixiums's CEO Khalid Ishaque and CFO Didier Laurens spoke to In Vivo during the Jefferies Healthcare 2017 conference (London) about the technology's progress. The directors (who also include Medtronic's Rob ten Hoedt, a former chairman of MedTech Europe), (Also see "Integrated Health Care Europe-style Is Here – Get Used To It" - In Vivo, 28 February, 2017

More from Innovation

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By Ian Taylor

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

More from In Vivo

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Rising Leaders 2025: Flagship’s Jacob Rubens On Building The Next Generation Of Biotech

 
• By David Wild

Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.